Drugs / Full Spectrum Microbiota
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03408886 | Jan 2018 → Apr 2022 overdue | autism spectrum disorder, digestive system disorder | Arizona State University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03110133 | May 2017 → Feb 2020 | Clostridium difficile colitis | Finch Research and Development LLC. | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Full Spectrum Microbiota | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03110133 ↗ |
| Known as | FSM | “followed by oral administration of Full Spectrum Microbiota (FSM) or placebo.” NCT03408886 ↗ |
| Action | Restore | “to restore a diverse microbiome” PMID 39366468 ↗ Oct 2024 |
| Modality | Other / unclassified | “CP101, an orally administered microbiome therapeutic” PMID 39366468 ↗ Oct 2024 |
| Route | Oral | “receive a single oral dose of either CP101” PMID 39366468 ↗ Oct 2024 |